ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 250 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 500 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup).benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 1000 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 2000 iu - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

ישראל - עברית - Ministry of Health

padagis israel agencies ltd, israel - factor viii (human) - אבקה להכנת תמיסה לזריקה - factor viii (human) 250 iu/vial - coagulation factor viii - coagulation factor viii - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor viii . koate-dvi provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia.

ישראל - עברית - Ministry of Health

padagis israel agencies ltd, israel - factor viii (human) - אבקה להכנת תמיסה לזריקה - factor viii (human) 500 iu/vial - coagulation factor viii - coagulation factor viii - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor viii . koate-dvi provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia.

ישראל - עברית - Ministry of Health

padagis israel agencies ltd, israel - factor viii (human) - אבקה להכנת תמיסה לזריקה - factor viii (human) 1000 iu/vial - coagulation factor viii - coagulation factor viii - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor viii . koate-dvi provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes, or in order to perform emergency and elective surgery on individuals with hemophilia.

ישראל - עברית - Ministry of Health

bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 1000 iu - coagulation factor viii

ישראל - עברית - Ministry of Health

bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 2000 iu - coagulation factor viii

ישראל - עברית - Ministry of Health

bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 250 iu - coagulation factor viii